Aaron Kantor
Head of Research Therini Bio
Aaron is a multidisciplinary scientist with over 30 years of relevant research and development experience. He joined Therini Bio in 2022 with a focus on translation sciences and biomarkers. He currently leads all research activity and supports our clinical trials. He has held leadership positions at the Immune Tolerance Institute, the Biomarker Discovery Sciences unit of Pharmaceutical Product Development, Gilead Sciences, the biomarker biotechnology start-up SurroMed Inc., and the therapeutic cell separation company AmCell. Throughout his career, Aaron has authored over 70 scientific publications and patents. He was a postdoctoral fellow at Stanford where his work focused on cellular and molecular aspects of B cell immunology and development of flow cytometry applications. He has a PhD in Biophysics from UC Berkeley and BA in Biophysics from the University of Pennsylvania.
Seminars
- Vascular dysfunction leads to the toxic accumulation of fibrin deposits outside of blood vessels, sparking chronic innate immune cell activation; this emerging pathway represents a novel, highly specific target for neurodegenerative disease intervention
- Targeting this pathway with highly specific antibodies restores a beneficial microglial population and is protective in preclinical models of Alzheimer’s disease, multiple sclerosis, and retinal diseases
- THN391, a first-in-class high-affinity humanized monoclonal antibody targeting the fibrin inflammatory epitope, is in Phase 1b trials for early Alzheimer's disease and diabetic macular edema
